Clopidogrel Platelet Function Tests
Caveats and Controversies
The FDA did not clarify what this warning meant for patients or clinicians. Should all patients on clopidogrel be tested or just new patients? Perhaps only patients with an adverse event while on clopidogrel should be tested or maybe all patients should be screened with a platelet function test first and the ones deemed resistant could go on to genetic testing. I sent this question along with several other questions to the FDA to the email address they provided in their boxed warning bulletin.
What Does Warning Mean For Clinicians?
Jump to section:
- Learning Objectives
- Platelet Function Tests for the Detection of Clopidogrel Resistance1
- Platelet Function Tests for the Detection of Clopidogrel Resistance
- Caveat: There Is No Perfect Platelet Function Test...
- Problems With Testing For Clopidogrel
- How We Choose a Testing Method
- Methodology Table
- Platelet Function Testing Available at Mayo Clinic Florida
- Light Transmission Platelet Aggregometry Studies (LTA)
- Platelet Aggregation (Cont'd)
- Normal Patient
- Accumetrics VerifyNow Test
- VerifyNow P2Y12 Test
- P2Y12 Test Interferences
- P2Y12 Antagonists2
- Can These Platelet Function Tests Be Used for Ticagrelor (Brilinta/Brilique)?
- PFA–100 (Cont'd)
- INNOVANCE PFA P2Y
- TEG — Platelet Mapping
- Results of VerifyNow Testing
- 2009–2011 Clopidogrel Response at 30%
- Genetic Testing: Clopidogrel Metabolism
- Clopidogrel Metabolism
- Number of Gene Polymorphisms
- Clopidogrel Metabolism and Genetic Polymorphisms
- Why Do Genetic Testing?
- Clopidogrel Genetics (Cont'd)
- Caveats — Other Reasons for Poor Response to Clopidogrel
- CYP2C19 Polymorphism May Require Another Factor
- Controversy for Clopidogrel
- Warning: Diminished Effectiveness In Poor Metabolizers
- What Does Warning Mean For Clinicians With Patients On Clopidogrel?
- FDA Answer
- More Questions